Genavent F.C.P.R. Net Worth

The estimated Net Worth of Genavent F.C.P.R. is at least 333 千$ dollars as of 7 May 2014. Genavent R owns over 10,000 units of Scynexis Inc stock worth over 332,637$ and over the last 11 years Genavent sold SCYX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Genavent R SCYX stock SEC Form 4 insiders trading

Genavent has made over 1 trades of the Scynexis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Genavent bought 10,000 units of SCYX stock worth 100,000$ on 7 May 2014.

The largest trade Genavent's ever made was buying 10,000 units of Scynexis Inc stock on 7 May 2014 worth over 100,000$. On average, Genavent trades about 10,000 units every 0 days since 2014. As of 7 May 2014 Genavent still owns at least 237,598 units of Scynexis Inc stock.

You can see the complete history of Genavent R stock trades at the bottom of the page.

What's Genavent R's mailing address?

Genavent's mailing address filed with the SEC is 90 BOULEVARD PASTEUR, CS 21564, PARIS CEDEX 15, I0, 75730.

Insiders trading at Scynexis Inc

Over the last 11 years, insiders at Scynexis Inc have traded over 4,708,140$ worth of Scynexis Inc stock and bought 2,173,590 units worth 13,469,713$ . The most active insiders traders include Advisors Llcperceptive Life...、Patrick Machado、Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of 64,694$. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth 225,000$.

What does Scynexis Inc do?

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Complete history of Genavent R stock trades at Scynexis Inc

Scynexis Inc executives and stock owners

Scynexis Inc executives and other stock owners filed with the SEC include:

• Dr. Marco Taglietti M.D.,
  CEO, Pres & Director
• Dr. Marco Taglietti,
  CEO, Pres & Director
• David Gonzalez Angulo,
  Chief Medical Officer
• Eric Francois,
  Chief Financial Officer
• Christine R. Coyne M.B.A.,
  Chief Commercial Officer
• Philippe Tinmouth,
  Director
• Jean-Yves Nothias,
  Director
• Guy Macdonald,
  Director
• Patrick Langlois,
  Director
• David Hastings,
  Director
• Ann Hanham,
  Director
• Steven Gilman,
  Director
• Laurent Arthaud,
  Director
• Armando Anido,
  Director
• David Angulo,
  Chief Medical Officer
• Scott Sukenick,
  General Counsel
• Nkechi Azie,
  Vice President - Clinical Development
• Jim Maffezzoli,
  Vice President of Sales and Marketing
• Eric Francois,
  Chief Financial Officer
• Marco Taglietti,
  President, Chief Executive Officer, Director
• Pamela Kirby,
  Chairman of the Board
• Debbie Etchison,
  Exec. Director of Communications
• Lawrence R. Hoffman CPA, Esq.,
  Interim CFO & Principal Accounting Officer
• Dr. Rajeshwar Motheram,
  Sr. VP of Pharmaceutical Devel. & Supply Chain
• Scott Sukenick J.D.,
  Gen. Counsel & Corp. Sec.
• Patrick Machado,
  Director
• Marion Mc Court,
  Director
• Jr. Charles F Osborne,,
  Chief Financial Officer
• Biopharma Partners Ii Lpalt...,
  
• Carole Sable,
  Chief Medical Officer
• Capital Ii Ventech,
  10% owner
• Biotechnology Fund Fcpr,
  10% owner
• Eileen Pruette,
  General Counsel
• Genavent F.C.P.R.,
  10% owner
• Mounia Chaoui,
  Director
• Edward Penhoet,
  Director
• Yves J Ribeill,
  President and CEO
• Advisors Llcperceptive Life...,
  
• Christine Coyne,
  Chief Commercial Officer
• Ivor Macleod,
  Chief Financial Officer